Abstracts tagged "longitudinal studies"

Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Hilde B Hammer¹, Lars Fritjof Karoliussen², Lene Terslev³, Espen A. Haavardsholm¹, Tore Kvien⁴ and Till Uhlig⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, ⁴RAID working group for EULAR, Zurich, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
Abstract Number: 240 • 2018 ACR/ARHP Annual Meeting
Bi-Directional Associations between “Too Much Sitting” and Self-Reported Pain in Patients with Rheumatoid Arthritis
Ciara O'Brien¹, Joan L. Duda¹, Jet J.C.S. Veldhuijzen van Zanten^1,2, George S. Metsios^2,3, George D. Kitas^1,2,4 and Sally A.M. Fenton^1,2, ¹School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³Faculty of Education Health & Wellbeing, University of Wolverhampton, Walsall, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom
Background/Purpose: Epidemiological evidence indicates that sedentary behaviour, or “too much sitting”, is associated with poor health outcomes in the general population, including elevated systemic inflammation.…
Abstract Number: 455 • 2018 ACR/ARHP Annual Meeting
Metabolic Syndrome and Trajectories of Pain Severity and Number of Painful Sites in Knee Osteoarthritis: Data from a 10.7-Year Prospective Study
Feng Pan¹, Jing Tian², Flavia Cicuttini³ and Graeme Jones⁴, ¹Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Public health unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ⁴Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Metabolic syndrome (MetS) has been suggested as having a role in osteoarthritis (OA) pathogenesis. No study has assessed whether MetS and its components are…
Abstract Number: 784 • 2017 ACR/ARHP Annual Meeting
Damage and Predictors of Damage in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel^1,14, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Information regarding the degree and the predictors of damage in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to characterize damage and…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…
Abstract Number: 1248 • 2017 ACR/ARHP Annual Meeting
Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Zsuzsanna McMahan¹, Tracy M. Frech², David Lim³, Veronica J. Berrocal⁴, Cosimo Bruni⁵, Marco Matucci-Cerinic⁶, Vanessa Smith⁷, Karin Melsons⁸, Susanna Proudman⁹, Jinyu Zhang¹⁰, Fabian A Mendoza¹¹, Melanie Woods³ and Dinesh Khanna³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Michigan, Ann Arbor, MI, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁶Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ⁷Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ⁸Ghent University, Gent, Belgium, ⁹Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹⁰Thomas Jefferson University, Philadelphia, PA, ¹¹Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The UCLA SCTC GIT 2.0 and NIH PROMIS GI Symptoms Scales are validated in scleroderma to assess patient-reported gastrointestinal (GI) involvement. We sought to…
Abstract Number: 1277 • 2017 ACR/ARHP Annual Meeting
Longitudinal Predictors of Physical Function in Juvenile Myositis
Kaveh Ardalan^1,2, Hannah L. Palac^3,4, Julia (Jungwha) Lee⁴, Madison Wolfe^5,6, Gabrielle A. Morgan^7,8 and Lauren M. Pachman⁹, ¹Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Abbvie, Inc, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁸Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile myositis (JM) is marked by skin rashes, proximal muscle weakness, and deconditioning causing potentially severe disability. Studies examining long-term physical function in JM…
Abstract Number: 1500 • 2017 ACR/ARHP Annual Meeting
Longitudinal Analysis of Different Therapeutic Strategies in Patients with Primary Sjögren’s Syndrome
Kristen Davies¹, Kamran Mirza¹, Jessica Tarn², Marian Regan³, Saravanan Vadivelu⁴, Gavin Clunie⁵, Jacqueline Andrews⁶, Elizabeth Price⁷, Steve Young-Min⁸, Ian Giles⁹, Bhaskar Dasgupta¹⁰, Cathy Lawson¹¹, Nagui Gendi¹², Neil J. McHugh¹³, Michele Bombardieri¹⁴, Costantino Pitzalis¹⁴, Nurhan Sutcliffe¹⁴, Simon Bowman¹⁵, Dennis Lendrem^16,17 and Wan-Fai Ng^2,18, ¹Institute of Cellular Medicine, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK, Newcastle-Upon-Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK, Newcastle-Upon-Tyne, United Kingdom, ³Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ⁴Queen Elizabeth Hospital, Gateshead, UK, Gateshead, United Kingdom, ⁵Ipswich Hospital NHS Trust, Ipswich, UK, Ipswich, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁷Great Western Hospital, Swindon, UK, Swindon, United Kingdom, ⁸Queen Alexander Hospital, Portsmouth, UK, Portsmouth, United Kingdom, ⁹Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, UK, London, United Kingdom, ¹⁰Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ¹¹Harrogate District Hospital, Harrogate, UK, Harrogate, United Kingdom, ¹²Basildon and Thurrock University Hospital, Basildon, UK, Basildon, United Kingdom, ¹³Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ¹⁴Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, UK, London, United Kingdom, ¹⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ¹⁶Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK, Newcastle-upon-Tyne, United Kingdom, ¹⁷Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK, Newcastle, United Kingdom, ¹⁸Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK, Newcastle-Upon-Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune rheumatic disease characterised by sicca features and systemic manifestations such as pain and fatigue. The classic…
Abstract Number: 1613 • 2017 ACR/ARHP Annual Meeting
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Noelle M. Teske¹, Khor Jia Ker^2,3, Rui Feng⁴, Benjamin F. Chong¹ and Victoria P Werth⁵, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Dermatology, National Skin Centre, Singapore, Singapore, ³Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: The natural disease course of patients with cutaneous lupus erythematosus (CLE) on standard-of-care treatments is not fully characterized. We sought to characterize their disease…
Abstract Number: 1642 • 2017 ACR/ARHP Annual Meeting
Role of Plaque in Predicting Cardiovascular Events in Women with Lupus over a 20 Year Followup
Erika Joyce¹, Linda Santelices², Jennifer Mall², Kristy Huysman², Amy Xiaoqin Tang³, Michael Anderson², Jennifer Elliott⁴, Amy H. Kao^5,6 and Susan Manzi², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Medicine, Allegheny Health Network, Pittsburgh, PA, ³Lupus Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA), Billerica, MA
Background/Purpose: The increased risk of premature cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) patients has been well reported. Multiple series have demonstrated a higher…
Abstract Number: 1668 • 2017 ACR/ARHP Annual Meeting
Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage
Mikhail Olferiev¹, Dina Greenman², David Fernandez¹, Kerry Merritt¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Up to 60% of SLE patients develop renal involvement, and renal injury is an important predictor of mortality in patients with SLE. Kidney biopsy…
Abstract Number: 2131 • 2017 ACR/ARHP Annual Meeting
Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation
Rebecca De Lorenzo¹, Iago Pinal-Fernandez², Maria Casal-Dominguez², Wilson Huang², Jose Cesar Milisenda¹, Cassie Parks², Katherine Pak³, Cheilonda Johnson⁴, Eleni Tiniakou⁵, Jemima Albayda⁶, Julie J. Paik⁶, Sonye K. Danoff⁷, Lisa Christopher-Stine⁷, Andrea Corse⁸ and Andrew Mammen^3,9, ¹Muscle Disease Unit, NIAMS, NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Neurology, Johns Hopkins University, Baltimore, MD, ⁹Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To describe the clinical and serologic features, as well as the disease course and response to therapy of anti-PM/Scl patients. Methods: All Johns Hopkins…
Abstract Number: 2138 • 2017 ACR/ARHP Annual Meeting
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM) are systemic inflammatory diseases that affect skeletal muscle, skin, and other organs, such as lungs,…
Abstract Number: 2880 • 2017 ACR/ARHP Annual Meeting
Clinical Evolution of Patients with Inflammatory Back Pain: A Population-Based Longitudinal Cohort Study
Runsheng Wang¹, Cynthia S. Crowson², Kerry Wright³ and Michael Ward⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴NIH/NIAMS, Bethesda, MD
Title: Clinical Evolution of Patients with Inflammatory Back Pain: a Population-Based Longitudinal Cohort Study Authors: Runsheng Wang1, Cynthia Crowson2, Kerry Wright2, Michael Ward31. Columbia University…
Abstract Number: 2942 • 2017 ACR/ARHP Annual Meeting
One Year Changes in Ultrasound Findings in the Feet Are Associated with Patient Reported Outcomes but Not Clinical Examination: a Prospective Observational Study of Patients with Early Rheumatoid Arthritis
Hanyan Zou¹, Karen A. Beattie², George Ioannidis³ and Maggie Larche², ¹McMaster University, Hamilton, ON, Canada, ²Medicine, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Despite extensive involvement of the feet in early RA, few studies report clinical and imaging changes in the feet over time. In this observational…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].